AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis
AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C
Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients
Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs
Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients
88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections
